NVAX
$10.64
Novavax, Inc., a biotechnology company, engages in the discovery, development, and commercialization of vaccines to prevent serious infectious diseases in the United States, Europe, and internationally.
Recent News
Here is What to Know Beyond Why Novavax, Inc. (NVAX) is a Trending Stock
Novavax (NVAX) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Is Trending Stock Novavax, Inc. (NVAX) a Buy Now?
Novavax (NVAX) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Assessing Novavax (NVAX) Valuation After Surprise Q4 Profitability And New Pfizer Licensing Deal
Novavax (NVAX) is back in focus after Q4 2025 results showed surprise profitability, with revenue of US$147.14 million and net income of US$17.53 million, supported by key vaccine partnerships and milestone payments. See our latest analysis for Novavax. The latest earnings surprise has come after a sharp move in the share price, with a 1 day share price return of a 9.38% decline following a strong 90 day share price return of 43.83% and a 1 year total shareholder return of 21.73%. However,...
How The Novavax (NVAX) Story Is Shifting Toward Licensing Income And COVID Recalibration
Novavax’s modeled fair value has been reset to US$13.78 from US$13.11, a small move that still matters if you are tracking how assumptions are shifting. Behind that change, recent Street research blends cautious optimism with ongoing concern, as analysts rework their views on the COVID franchise, expense profile, and the contribution from licensing income. Read on to see what is driving these revisions and how you can keep up with the evolving story around Novavax. Stay updated as the Fair...
Novavax Profit And Partnership Pivot Reframe Risk And Valuation Story
Novavax (NasdaqGS:NVAX) reported a surprise profit for the fourth quarter, alongside revenue that was above prior expectations. The company is shifting its business model by transferring commercialization of its COVID-19 vaccine Nuvaxovid to Sanofi. Novavax plans to focus on a partnership-driven approach centered on milestone payments, royalties, and advancing its pipeline. For you as an investor, the key change is that Novavax is moving away from directly commercializing Nuvaxovid and...